Decreased expression of the endothelial cell-derived factor EGFL7 in systemic sclerosis: potential contribution to impaired angiogenesis and vasculogenesis by Manetti, Mirko et al.
Decreased expression of the endothelial
cell-derived factor EGFL7 in systemic sclerosis:
potential contribution to impaired angiogenesis
and vasculogenesis
Manetti et al.
Manetti et al. Arthritis Research & Therapy 2013, 15:R165
http://arthritis-research.com/content/15/5/R165
Manetti et al. Arthritis Research & Therapy 2013, 15:R165
http://arthritis-research.com/content/15/5/R165RESEARCH ARTICLE Open AccessDecreased expression of the endothelial
cell-derived factor EGFL7 in systemic sclerosis:
potential contribution to impaired angiogenesis
and vasculogenesis
Mirko Manetti1*, Serena Guiducci2, Eloisa Romano2, Jérôme Avouac3,4, Irene Rosa1, Barbara Ruiz3,4, Gemma Lepri2,
Silvia Bellando-Randone2, Lidia Ibba-Manneschi1, Yannick Allanore3,4 and Marco Matucci-Cerinic2Abstract
Introduction: Microvascular damage and defective angiogenesis and vasculogenesis have a major role in the
pathogenesis of systemic sclerosis (SSc). Epidermal growth factor-like domain 7 (EGFL7) is a proangiogenic molecule
which is predominantly expressed and secreted by endothelial cells and their progenitors and controls vascular
development and integrity. In this study, we investigated the possible involvement of EGFL7 in SSc.
Methods: Serum EGFL7 levels from 60 patients with SSc and 35 age- and sex-matched healthy controls were
examined by colorimetric sandwich enzyme-linked immunosorbent assay. The expression of EGFL7 in forearm skin
biopsies (n = 16 SSc, n = 10 controls), cultured dermal microvascular endothelial cells (MVECs) (n = 3 SSc, n = 3
controls) and late-outgrowth peripheral blood endothelial progenitor cell (EPC)-derived endothelial cells
(n = 15 SSc, n = 8 controls) was investigated by immunofluorescence and Western blotting.
Results: Serum EGFL7 levels were detectable in 68.6% of healthy controls and 45% of SSc cases (P < 0.05).
Circulating levels of EGFL7 were significantly decreased in SSc patients compared with healthy controls (P = 0.01).
Serum levels of EGFL7 were significantly lower in both limited cutaneous SSc and diffuse cutaneous SSc patients
than in controls (P = 0.02 and P = 0.04, respectively). In SSc, decreased serum EGFL7 levels were significantly
correlated with the severity of nailfold capillary abnormalities. Patients with the most severe capillary changes and
digital ulcers had serum EGFL7 levels significantly lower than healthy controls, while the EGFL7 levels did not differ
significantly between controls and SSc patients with less capillary damage and lack of digital ulcers. Endothelial
EGFL7 expression was strongly downregulated or even almost completely undetectable in SSc-affected dermis
compared with controls (P < 0.001). In cultured SSc dermal MVECs and late-outgrowth peripheral blood EPC-derived
endothelial cells, EGFL7 was significantly downregulated compared with cells obtained from healthy subjects
(P < 0.01 and P < 0.001, respectively).
Conclusions: Our findings suggest that the loss of EGFL7 expression in endothelial cells and their progenitors
might play a role in the development and progression of peripheral microvascular damage and the defective
vascular repair process characteristic of SSc.* Correspondence: mirkomanetti@yahoo.it
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Table 1 Demographic and clinical characteristics of the
60 patients with SSc used for collection of serum samples
Characteristic Systemic sclerosis
(SSc) patients
Age, years, median (range) 56 (24 to 73)
Sex,
Male 4 (6.7)
Female 56 (93.3)
Disease subset,
lcSSc 37 (61.7)
dcSSc 23 (38.3)
Disease duration, years, median (range)a 7 (1 to 17)
Autoantibody positivity,
ANA 56 (93.3)
Anti-Scl-70 20 (33.3)
ACA 25 (41.7)
Digital ulcers 25 (41.7)
Nailfold videocapillaroscopy pattern,
Early 21 (35.0)
Active 24 (40.0)
Late 15 (25.0)
Skin score, median (range)b 10 (3 to 41)
Interstitial lung diseasec 24 (40.0)
Except where indicated otherwise, values are the number (%) of subjects.
aDisease duration was calculated since the first non-Raynaud’s symptom of
SSc; bmodified Rodnan skin thickness score; cdetermined by high-resolution
computer tomography. ACA, anticentromere antibodies; ANA, antinuclear
antibodies; Anti-Scl-70, anti-Scl-70 antibodies; dcSSc, diffuse cutaneous SSc;
lcSSc, limited cutaneous SSc.
Manetti et al. Arthritis Research & Therapy 2013, 15:R165 Page 2 of 8
http://arthritis-research.com/content/15/5/R165Introduction
Systemic sclerosis (SSc, or scleroderma) is a chronic con-
nective tissue disorder characterized by widespread micro-
vascular injury, fibrosis and autoimmunity that affects the
skin and internal organs [1]. In SSc, Raynaud’s pheno-
menon is the earliest clinical manifestation paralleled by
nailfold capillaroscopic alterations that may occur months
or even years before the onset of fibrosis. In the overall
disease pathogenesis, this evidence suggests a crucial role
of microvasculopathy characterized by a progressive and
irreversible loss of capillaries and lack of compensatory
angiogenesis/vasculogenesis often leading to severe peri-
pheral ischemic manifestations [2,3].
Epidermal growth factor-like domain 7 (EGFL7), also
known as vascular endothelial statin, is a recently dis-
covered secreted protein that is expressed by and acts
on endothelial cells and their mesodermal progenitors to
control blood vessel development and integrity during
both physiological and pathological vasculogenesis and
angiogenesis [4,5]. Increasing evidence suggests that
EGFL7 regulates blood vessel development by creating a
permissive environment for angiogenesis [5]. The prin-
cipal mechanism by which this occurs is by promoting
endothelial cell proliferation, migration, sprouting and
invasion [5-8]. Indeed, EGFL7 loss-of-function mouse
models exhibit partial embryonic lethality and serious
vascular abnormalities [7]. Moreover, EGFL7 plays a role
in the repair of the microvasculature in response to vas-
cular injury and ischemia [5,8]. Accordingly, increased
levels of EGFL7 are detected in response to hypoxia in
endothelial cells both in vitro and in vivo and stimulate
an angiogenic response [9,10]. Finally, EGFL7 has a pro-
tective role against vascular injury by repressing key
steps in the inflammatory activation of endothelial cells
in response to hypoxia/reoxygenation [9,11].
On this basis, we hypothesized that EGFL7 might play
a role in SSc pathogenesis. Therefore, the aim of the
present study was to investigate whether the expression
of EGFL7 could be altered in the circulation, skin and
endothelial cells of SSc patients.
Methods
Patients, controls, serum samples and skin biopsy samples
Serum samples were obtained from 60 patients with SSc
(56 women and 4 men; median age 56 years, range 24 to
73 years, and median disease duration 7 years, range 1
to 17 years), classified as limited cutaneous SSc (lcSSc;
n = 37) or diffuse cutaneous SSc (dcSSc; n = 23) according
to LeRoy et al. [12], and from 35 age- and sex-matched
healthy individuals. All patients reported the occurrence
of Raynaud’s phenomenon. At the time blood was drawn,
the presence of digital ulcers was recorded. Nailfold video-
capillaroscopy (NVC) was performed on all 10 fingers by
a single rheumatologist and images were scored blindly todivide patients into three capillaroscopic patterns (that is,
early, active and late) [13,14]. Table 1 shows the clini-
codemographic characteristics of SSc patients used for
collection of serum samples. Patients were not taking
immunosuppressive medications, corticosteroids or other
potentially disease-modifying drugs. Before blood sam-
pling, they were washed out for 10 days from oral
vasodilating drugs and for 2 months from intravenous
prostanoids. Fresh venous blood samples were drawn, left
to clot for 30 minutes before centrifugation at 1,500 g for
15 minutes, and serum was collected and stored in
aliquots at −80°C until used. Paraffin-embedded sections
of lesional forearm skin biopsies were obtained from
16 SSc patients (14 women and 2 men; n = 9 with lcSSc
and n = 7 with dcSSc; median age 46.8 years, range 27 to
69 years, and median disease duration 6 years, range 1 to
16 years) and 10 age- and sex-matched healthy donors, as
described elsewhere [14,15]. The study was approved
by the local institutional review board at the Azienda
Ospedaliero-Universitaria Careggi (AOUC), Florence,
Italy, and all subjects provided written informed consent.
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Dermal microvascular endothelial cells (MVECs) were iso-
lated from biopsy samples of the involved forearm skin
from three patients with dcSSc and from three healthy
subjects, as described elsewhere [14]. Patients were not
taking immunosuppressive or disease-modifying drugs at
the time of biopsy. Briefly, skin biopsy samples were
mechanically cleaned of epidermis and adipose tissue in
order to obtain a pure specimen of vascularized dermis,
and were treated as previously described [14]. Colonies of
polygonal elements were detached with ethylenediamine-
tetraacetic acid, and CD31-positive cells were subjected to
immunomagnetic isolation. Isolated cells were further
identified as MVECs by labeling with anti-factor VIII-
related antigen and anti-CD105, followed by reprobing
with anti-CD31 antibodies. MVECs were maintained in
MCDB medium (Sigma-Aldrich, St Louis, MO, USA) sup-
plemented with 30% fetal bovine serum, 20 μg/ml endo-
thelial cell growth supplement (Calbiochem, Nottingham,
UK), 10 μg/ml hydrocortisone, 15 IU/ml heparin, and
antibiotics. MVECs were used between the third and
seventh passages in culture.
Late-outgrowth peripheral blood endothelial progenitor
cell-derived endothelial cells
Late-outgrowth endothelial progenitor cell (EPC)-derived
endothelial cells were obtained from the peripheral blood
of 15 SSc patients (13 women and 2 men; n = 9 with lcSSc
and n = 6 with dcSSc; median age 60 years, range 42 to
78 years) and 8 healthy individuals (all women; median
age 55 years, range 30 to 65 years), as described elsewhere
[16,17]. The study was approved by the local institutional
review board at the Cochin Hospital, Paris, France, and all
patients and control subjects provided written informed
consent. Briefly, EPC isolation was performed on a 50-ml
heparinized venous blood sample obtained from the fore-
arm. Samples from hospitalized patients were obtained in
the morning, at rest, during routine analysis. Patient and
control samples were immediately transported to the
laboratory for testing. The blood mononuclear cell frac-
tion was collected by Ficoll density-gradient centrifugation
and was resuspended in complete endothelial cell growth
medium 2 (EGM-2; Lonza, Basel, Switzerland). Cells
were then seeded onto separate wells of a 12-well tissue
culture plate precoated with type I collagen (rat tail; BD
Biosciences, Le Pont de Claix, France) and stored in an
atmosphere of 5% CO2 at 37°C in a humidified incubator.
After 24 hours of culture, non-adherent cells and debris
were aspirated, adherent cells were washed once with
PBS, and complete EGM-2 was added to each well. The
medium was changed daily for 7 days and then every
other day until the first passage. Colonies of endothelial
cells appeared between 8 and 26 days of culture and were
identified as well-circumscribed monolayers of cells with acobblestone appearance. After the third passage, pheno-
typing of EPC-derived cells was performed by flow cyto-
metry, as previously described [16]. After confirmation of
the endothelial phenotype, cells were suspended in fetal
bovine serum supplemented with 20% dimethyl sulfoxide,
frozen in liquid nitrogen, and stored until used.
ELISA for serum EGFL7
Serum EGFL7 levels were measured by colorimetric sand-
wich ELISA. First, 96-well microplates (R&D Systems,
Minneapolis, MN, USA) were coated overnight at 4°C
with rabbit polyclonal antihuman EGFL7 as a capture
antibody (2.5 μg/ml; Abnova, Taipei, Taiwan). The wells
were then washed twice with PBS with 0.1% Tween-20
and blocked for 2 hours at room temperature with 5%
BSA in PBS with 0.1% Tween-20. Standards and serum
samples (100 μl/well) were incubated for 2 hours at room
temperature. The microplates were washed three times
with PBS with 0.1% Tween-20, followed by the addition
of mouse monoclonal antihuman EGFL7 as a detection
antibody (1 μg/ml; Abnova) and horseradish peroxidase-
conjugated goat anti-mouse immunoglobulin G (IgG).
The reaction was developed with tetramethylbenzidine
and then stopped by applying sulfuric acid (2 N H2SO4)
(R&D Systems). The absorbance of each well was read
using a microplate reader at 450 nm. Serum levels of
EGFL7 were read from a standard curve prepared using
recombinant human EGFL7 protein (Abcam, Cambridge,
UK). The detection range of the assay was 0.3 to
30.0 ng/ml. Each sample was measured in duplicate.
Immunofluorescence
For antigen retrieval, paraffin-embedded skin sections
(5 μm thick) were deparaffinized and boiled for 10 minutes
in sodium citrate buffer (10 mM, pH 6.0). The sections
were washed three times in PBS, incubated in 2 mg/ml
glycine for 10 minutes to quench autofluorescence caused
by free aldehydes, and then blocked for 1 hour at room
temperature with 1% BSA in PBS. The slides were incu-
bated overnight at 4°C with mouse monoclonal antihuman
EGFL7 antibody (catalogue number ab50254, Abcam)
diluted 1:50 in PBS with 1% BSA. After extensive washing
in PBS, the sections were incubated with Rhodamine
Red-X-conjugated goat anti-mouse IgG (1:200 dilution;
Molecular Probes, Eugene, OR, USA) for 45 minutes at
room temperature in the dark. Irrelevant isotype-matched
and concentration-matched mouse IgG (Sigma-Aldrich)
were used as negative controls. For double immunofluo-
rescence staining, we used a rabbit polyclonal antibody
against CD31/pan-endothelial cell marker (1:50 dilution;
catalogue number ab28364, Abcam) followed by Alexa
Fluor-488-conjugated goat anti-rabbit IgG (1:200 dilution;
Molecular Probes). Nuclei were counterstained with 4′,6-
diamidino-2-phenylindole (DAPI) (Chemicon International,
Figure 1 Serum levels of epidermal growth factor-like domain
7 (EGFL7) determined by colorimetric sandwich ELISA.
(A) Serum EGFL7 levels in healthy controls, all patients with systemic
sclerosis (SSc), patients with limited cutaneous SSc (lcSSc) and
patients with diffuse cutaneous SSc (dcSSc). (B) Serum levels of
EGFL7 in patients with SSc according to nailfold videocapillaroscopy
pattern (early, active and late). Data are shown as box plots. Each box
represents the 25th to 75th percentiles. Lines inside the boxes
represent the median. Lines outside the boxes represent the 10th and
the 90th percentiles. Circles indicate outliers, and asterisks indicate the
extreme values. #P = 0.006 versus controls. Mann–Whitney U-test was
used for statistical analysis. NS, not significant.
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then observed under a Leica DM4000 B microscope
equipped with fully automated fluorescence axes (Leica
Microsystems, Mannheim, Germany). Fluorescence im-
ages were captured using a Leica DFC310 FX 1.4-megapixel
digital colour camera equipped with the Leica software
application suite LAS V3.8 (Leica Microsystems). Densito-
metric analysis of the intensity of immunofluorescent
staining was performed on digitized images using the free-
share ImageJ software (NIH, Bethesda, MD, USA; online
at http://rsbweb.nih.gov/ij).
Western blotting
Proteins were extracted from dermal MVECs and late-
outgrowth peripheral blood EPC-derived endothelial cells
as described elsewhere [14,17]. Twenty micrograms of
total proteins were electrophoresed on NuPAGE 4 to 12%
Bis-Tris Gel (Invitrogen, Carlsbad, CA, USA) and blotted
onto polyvinylidene difluoride membranes (Invitrogen).
The membranes were blocked with blocking solution
included in the Western Breeze Chromogenic Western
Blot Immunodetection Kit (Invitrogen) for 30 minutes at
room temperature on a rotary shaker and incubated for
1 hour at room temperature with mouse monoclonal anti-
human EGFL7 (1:500 dilution; Abcam) and rabbit poly-
clonal anti-α-tubulin (catalogue number #2144; 1:1,000
dilution; Cell Signaling Technology, Danvers, MA, USA)
antibodies, assuming α-tubulin as control invariant pro-
tein. Immunodetection was performed as described in the
Western Breeze Chromogenic Immunodetection protocol
(Invitrogen). Densitometric analysis of the bands was per-
formed using ImageJ software and the values normalized
to α-tubulin.
Statistical analysis
Data are expressed as the mean ± standard error of the
mean (SEM) or median and IQR. The Student t-test and
nonparametric Mann–Whitney U-test were used where
appropriate for statistical evaluation of the differences
between two independent groups. A P-value less than
0.05 was considered statistically significant.
Results
Serum EGFL7 levels were detectable in 68.6% of healthy
subjects and 45% of SSc patients (P <0.05, χ2 test). Cir-
culating levels of EGFL7 were significantly decreased in
SSc patients (median 0.0 ng/ml, IQR 0.0 to 4.1 ng/ml)
compared with healthy controls (median 4.2 ng/ml, IQR
0.0 to 10.3 ng/ml; P = 0.01) (Figure 1A). Serum EGFL7
levels were significantly lower both in lcSSc patients
(median 0.0 ng/ml, IQR 0.0 to 3.9 ng/ml) and dcSSc pa-
tients (median 0.0 ng/ml, IQR 0.0 to 5.3 ng/ml) than in
controls (P = 0.02 and P = 0.04, respectively) (Figure 1A).
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levels was detected between lcSSc and dcSSc (Figure 1A).
Next, we evaluated the possible correlation of serum
EGFL7 levels with the NVC pattern as a measure of peri-
pheral microvascular involvement. EGFL7 levels were
lower in SSc patients with late NVC pattern (median
0.0 ng/ml, IQR 0.0 to 2.7 ng/ml) than in those with early
(median 0.6 ng/ml, IQR 0.0 to 6.2 ng/ml) or active
(median 0.0 ng/ml, IQR 0.0 to 7.1 ng/ml) patterns, but
these differences did not reach statistical significance
(Figure 1B). Serum EGFL7 levels were significantly
decreased in SSc patients with late NVC pattern comparedFigure 2 Decreased expression of epidermal growth factor-like doma
endothelial cells (MVEC) of patients with systemic sclerosis (SSc). (A-F
controls (A-C; n = 10) and SSc patients (D-F; n = 16) immunostained for EG
(DAPI; blue) for nuclei. Arrows indicate microvessels. (G and H) Representa
SSc patients (H) double immunostained for EGFL7 (red) and the pan-endo
Original magnification and scale bars are indicated in each panel. (I) Densit
microvessels expressed as optical density in arbitrary units (a.u.). Data are sh
Lines inside the boxes represent the median. Lines outside the boxes repre
for statistical analysis. (J) Western blotting of protein lysates from control d
antibodies. Representative immunoblots are shown. The densitometric analys
Data are mean ± standard error of the mean of optical density in a.u. Studentwith healthy controls (P = 0.006), whereas although de-
creased, no significant difference in EGFL7 levels could be
found between SSc patients with early or active NVC
patterns and controls (Figure 1B). A trend toward re-
duction in the circulating levels of EGFL7 was observed
in SSc patients with digital ulcers (median 0.0 ng/ml,
IQR 0.0 to 2.2 ng/ml) compared with those without
digital ulcers (median 0.6 ng/ml, IQR 0.0 to 8.0 ng/ml;
P = 0.08). Moreover, EGFL7 levels were significantly
lower in SSc patients with digital ulcers than in controls
(P = 0.002), whereas no difference was detected when
comparing the group of SSc patients without digital ulcersin 7 (EGFL7) in the affected skin and dermal microvascular
) Representative microphotographs of skin sections from healthy
FL7 (red) and counterstained with 4′,6-diamidino-2-phenylindole
tive microphotographs of skin sections from healthy controls (G) and
thelial cell marker CD31 (green) and counterstained with DAPI (blue).
ometric analysis of EGFL7 immunofluorescent staining in dermal
own as box plots. Each box represents the 25th to 75th percentiles.
sent the 10th and the 90th percentiles. Mann–Whitney U-test was used
ermal MVEC (n = 3) and SSc MVEC (n = 3) analyzed using anti-EGFL7
is of the bands normalized to α-tubulin is reported in the histograms.
t-test was used for statistical analysis.
Figure 3 Decreased expression of epidermal growth factor-like
domain 7 (EGFL7) in late-outgrowth peripheral blood endothelial
progenitor cell (EPC)-derived endothelial cells from patients with
systemic sclerosis (SSc). Western blotting of protein lysates from
control (n = 8) and SSc (n = 15) late-outgrowth peripheral blood
EPC-derived endothelial cells analyzed using anti-EGFL7 antibodies.
Representative immunoblots are shown. The densitometric analysis
of the bands normalized to α-tubulin is reported in the histograms.
Data are mean ± standard error of the mean of optical density in
arbitrary units (a.u.). Student t-test was used for statistical analysis.
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other clinicodemographic and laboratory parameters.
The expression of EGFL7 protein in forearm skin bi-
opsies from SSc patients and controls was investigated
by immunofluorescence. Constitutive EGFL7 expression
was observed in dermal endothelial cells from healthy
control skin (Figure 2A-C). Endothelial EGFL7 expres-
sion was strongly downregulated or even almost un-
detectable in SSc-affected dermis (Figure 2D-F). The
localization of EGFL7 staining in vascular endothelial
cells was confirmed by EGFL7/CD31 double immu-
nofluorescence staining (Figure 2G,H). Densitometric
analysis of immunofluorescent staining intensity on skin
sections showed that EGFL7 protein expression was sig-
nificantly decreased in dermal vessels of SSc patients
compared with controls (P <0.001) (Figure 2I). No sig-
nificant differences in dermal expression of EGFL7 were
observed according to disease duration or cutaneous
SSc subsets. Moreover, Western blot analysis revealed
that EGFL7 protein expression levels were significantly
reduced in MVECs isolated from dcSSc dermis com-
pared with control dermal MVECs (P <0.01) (Figure 2J).
Consistent with skin and dermal MVEC findings, EGFL7
protein levels were significantly lower in late-outgrowth
peripheral blood EPC-derived endothelial cells from SSc
patients than in cells obtained from healthy controls
(P <0.001; Figure 3). No obvious differences in EGFL7
levels could be found between late-outgrowth EPC-derived
endothelial cells from lcSSc and dcSSc patients.
Discussion
This is the first study to investigate the possible involve-
ment of the recently identified angiogenic signaling mol-
ecule EGFL7 in the pathogenesis of SSc. Our data show
that serum levels and dermal expression of EGFL7 are
significantly decreased in SSc patients. Remarkably, the
decrease of serum EGFL7 levels in SSc patients corre-
lated with the severity of nailfold capillary abnormalities.
In contrast to constitutive endothelial cell expression of
EGFL7 in healthy skin, EGFL7 was found to be strongly
reduced or even undetectable in SSc dermal micro-
vessels. Furthermore, EGFL7 protein was found to be
significantly downregulated in vitro both in dermal
MVECs and peripheral blood EPC-derived endothelial
cells obtained from SSc patients compared with the res-
pective control cells. Taken together, our findings sug-
gest that the loss of EGFL7 expression might play a role
in the development and progression of peripheral micro-
vascular damage and defective vascular repair process in
SSc patients.
The majority of secreted angiogenic signaling mole-
cules are expressed not only by endothelial cells but also
by a plethora of other cell types, such as macrophages,
fibroblasts, smooth muscle cells and epithelial cells [5].In this context, EGFL7 is unique because it is almost
exclusively expressed by and acts on endothelial cells
[5-8,18]. During embryogenesis, EGFL7 expression is de-
tected at sites of both extra-embryonic and embryonic
mesodermal progenitors and in vascular structures that
arise by vasculogenesis [4-6]. Most adult tissues express
EGFL7 in a subset of vessels, however, the levels are
considerably lower in quiescent endothelium than in the
embryo [6,8]. EGFL7 expression is elevated in the
proliferating endothelium of the pregnant uterus, and
increased levels are observed during tumorigenesis or
endothelial regeneration subsequent to vascular injury,
suggesting that it plays a role during both physiological
and pathological angiogenesis and vascular remodeling
[5,6,8,18]. Indeed, EGFL7 regulates multiple steps in
the angiogenic cascade, including endothelial cell proli-
feration, migration, adhesion, sprouting and invasion
[5-8,19]. In particular, it has been recently demonstrated
that EGFL7 promotes angiogenesis mainly via its inter-
action with the integrin αvβ3 receptor [20]. EGFL7
is secreted by endothelial cells into the extracellular
matrix, where it affects the process of lumen formation
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within the EGFL7 gene, may also have a major role in
vessel development by promoting vascular endothelial
growth factor signaling, angiogenesis and vascular in-
tegrity [21]. Recent studies suggest a protective role for
EGFL7 against vascular injury and ischemia. In support,
EGFL7 expression is temporarily induced in regene-
rating endothelium of mice that have been subjected to
arterial vascular insult [8]. Interestingly, an increase in
the levels of EGFL7 under hypoxic conditions appears
not only to stimulate compensatory angiogenesis, but
also to repress key steps in the inflammatory activation
of endothelial cells in response to ischemia/reperfusion
injury [5,9,10].
In this context, the correlation of serum EGFL7 levels
with the severity of SSc-related peripheral microvascu-
lar damage appears to be of major importance. In fact,
serum EGFL7 levels progressively decreased reaching
the lowest values in SSc patients with the late NVC pat-
tern, which is characterized by substantial loss of capil-
laries with formation of avascular areas [13]. Moreover,
patients with most severe capillary changes and digital
ulcers had serum EGFL7 levels significantly lower than
healthy controls, whereas the EGFL7 levels did not dif-
fer significantly between controls and SSc patients with
less capillary damage and lack of digital ulcers. Despite
the hypoxic microenvironment of SSc skin [3,22],
the expression of EGFL7 was strongly downregulated
ex vivo in dermal microvessels from lesional forearm
skin biopsies. Finally, EGFL7 downregulation was con-
sistently observed in vitro not only in SSc dermal
MVECs, but also in peripheral blood EPC-derived endo-
thelial cells, thus indicating that EGFL7 signaling de-
fects may even originate in committed endothelial
lineage progenitors. Collectively, these findings suggest
that failure to induce EGFL7 expression following endo-
thelial cell activation/damage might have a role in the
defective vascular repair process of SSc. However, since
EGFL7 is specifically released by endothelial cells, we
should also consider that the reduction in circulating
levels of EGFL7 might be either a cause or a conse-
quence of the disease, which is characterized by pro-
gressive loss of the peripheral microcirculation [3].
Serum levels of EGFL7 could even serve as a biomarker
reflecting the severity of microvascular involvement
in SSc.
Conclusions
In summary, we shed light on EGFL7 as a possible new
player in the vascular component of SSc pathogenesis.
Further functional studies are now required to ascertain
whether restoration of endothelial EGFL7 expression
might offer new targeted therapeutic strategies to control
the progression of peripheral microvasculopathy in SSc.Abbreviations
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